# Sartorius account plan

> Sartorius is a Göttingen-based life science group supplying biopharma research and production, with €3,538.1 million 2025 sales and 14,042 employees.

## At a glance

Sartorius, founded in 1870 and headquartered in Göttingen, Germany, supplies the biopharmaceutical industry and life science research with products to develop and manufacture biotech medications and vaccines, from cell lines and bioreactors to filtration, single-use consumables, lab instruments and bioanalytics. Its customers are pharma and biotech companies, CDMOs, academic institutes and quality-control labs, and more than 90% of sales are generated outside Germany. In 2025 sales revenue was €3,538.1 million (+7.6% in constant currencies), underlying EBITDA €1,051.6 million (margin 29.7%) and relevant net profit €330.7 million, with 14,042 employees at year-end. Sartorius AG is listed in Frankfurt and holds 71.5% of the Euronext-listed Sartorius Stedim Biotech.

## Business units

- **Bioprocess Solutions** (81% of 2025 group sales (€2,865.0 million)): The full process chain for producing biologics, from cell culture media and bioreactors to filtration, chromatography and fluid management, sold mostly direct to pharma, biotech and contract manufacturers through Sartorius Stedim Biotech; 10,878 employees, led by Dr. René Fáber. 2025 sales grew 9.5% in constant currencies with a 31.7% margin, and recurring single-use products are just above three-quarters of sales.
- **Lab Products & Services** (19% of 2025 group sales (€673.0 million)): Bioanalytics (Incucyte, Octet, iQue), lab balances, pipettes, water systems, consumables and services, sold to research and QC labs; 3,164 employees, led by Dr. Alexandra Gatzemeyer. 2025 sales were stable (+0.2% cc) with a 21.5% margin; H1 2026 operational growth was 5.3%, helped by the MATTEK 3D cell model acquisition.

## Strategic priorities

- **Mid-term growth targets**: Set at the March 2026 Capital Markets Day: organic growth of 8 to 11% a year from 2027 (Bioprocess 9 to 12%, Lab 5 to 7%) and underlying EBITDA margin expansion of about 50 to 75 basis points a year.
- **AI in drug development and bioprocessing**: The CEO sees AI as the largest potential to shorten development times; Corporate Research works on AI, in-silico simulation and predictive models, and Incucyte's AI image analysis won 3 new top-10 pharma customers this year.
- **Continuous and intensified manufacturing**: The Pionic platform developed with Sanofi, now with Quad & Cross modules for fully integrated continuous downstream processing, sees demand above initial expectations.
- **Regional growth**: Grow in North America, where its share was historically lower, and in Asia, including a new consumables plant in Songdo, South Korea.
- **Process optimization**: Capacity, a resilient supply chain, digital customer interfaces and ERP and CRM digitalization, including the S/4 HANA conversion.

## Latest results

In H1 2026 sales revenue was €1,810.9 million, up 7.7% operationally in constant currencies excluding customer compensation for refunded US tariffs, and 6.2% including it. Consumables and services drove growth while equipment and instruments returned to modest growth. Underlying EBITDA rose 3.9% to €547.8 million (margin 30.3%), net profit after minorities rose to €122.2 million and free cash flow increased 70.4% to €207.7 million. Asia | Pacific grew 12.1% on a recovery in China. Guidance for 2026 was confirmed at group sales growth of around 5 to 9% in constant currencies and a margin slightly above 30%.

## Investments and deals

- **Songdo, South Korea**: The largest 2025 project and a significant share of 2026 capex: sterile consumables production plus a technology center and labs for Asia | Pacific.
- **European site expansion**: A competence center for cell and gene therapy materials in Freiburg, membrane and filter capacity in Göttingen, nearly doubled cleanroom space in Aubagne and a transfection reagent plant in Illkirch.
- **Capex programme**: Capex was €441.9 million in 2025 (12.5% of sales); 2026 is the last elevated year, with the capex ratio to come down from 2027.
- **Acquisitions and buyouts**: MATTEK acquired July 1, 2025; the remaining 24% of Sartorius CellGenix was bought for about €71.8 million and the remaining stake in Sartorius Automated Lab Solutions for €14.0 million in 2026.
- **Refinancing**: A €500 million, 3.75% bond issued in May 2026 refinanced early the bond maturing in September 2026.

## Challenges and risks

- **Equipment investment restraint**: Customers remained reluctant to invest in equipment because of pandemic-era overcapacity, and US reshoring orders are expected mostly in H2 2027 with sales in 2028 and beyond.
- **US tariffs**: A 15% US tariff applies to most EU imports, and tariff refund compensation to customers could reduce 2026 revenue by up to €40 million versus initial assumptions.
- **Advanced therapies volatility**: Delayed late-stage orders at 2 advanced-therapy customers diluted recurring growth, and the gene therapy segment is developing below medium- to long-term expectations.
- **Leverage**: Net debt was €3,761.1 million at June 30, 2026 with leverage of 3.51, after S&P cut the rating to BBB- in 2025.
- **Competition**: Danaher, Merck KGaA and Thermo Fisher compete in both divisions, plus Mettler-Toledo, Eppendorf, Agilent, Becton Dickinson and Revvity in lab products.

## What leadership says

> "If done right, it might become the biggest transformation in our industry" — Michael Grosse, CEO, CEO interview in the Annual Report 2025, on AI

> "Leveraging AI to drive a step change in speed of drug discovery and in productivity or bioprocessing is becoming a must." — Michael Grosse, CEO, H1 2026 results call, July 23, 2026

> "we will not celebrate if we achieve only a 6% growth for 2026." — Michael Grosse, CEO, Preliminary 2025 results call, February 3, 2026

> "We stay committed to our investment-grade rating." — Florian Funck, CFO, Preliminary 2025 results call, February 3, 2026


## Where a supplier can help

- **AI and data for R&D**: The CEO's AI agenda and Corporate Research work on in-silico simulation and predictive models open doors for AI, data and software partners.
- **Plant build-out and automation**: The Songdo plant, Freiburg and Göttingen expansions and elevated 2026 capex point to engineering, cleanroom, automation and equipment suppliers.
- **ERP, CRM and digital interfaces**: The process-optimization priority, including the S/4 HANA conversion, ERP and CRM digitalization and digital customer interfaces, suits IT integrators and software vendors.
- **Supply chain and logistics**: A resilient supply chain is a stated focus, sterilization, packaging and logistics are largely outsourced, and tariffs and Middle East freight costs add pressure.
- **North American growth**: The push to gain share in North America and capture reshoring projects fits commercial, channel and market-access partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Sartorius Group Annual Report 2025](https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf)

Annual report · 2026-02-16

- Sartorius is a Göttingen-based life science group (founded 1870) serving biopharmaceutical research and production; 2025 sales revenue was €3,538.1 million, up 7.6% in constant currencies (4.7% reported), with 14,042 employees at year-end.
- Two divisions: Bioprocess Solutions (81% of sales, €2,865.0 million, +9.5% cc, underlying EBITDA margin 31.7%), run through the Euronext-listed Sartorius Stedim Biotech (71.5% owned), and Lab Products & Services (19%, €673.0 million, +0.2% cc, margin 21.5%).
- Underlying EBITDA rose 11.2% to €1,051.6 million (margin 29.7% vs 28.0%); relevant net profit rose 18.2% to €330.7 million; net debt to underlying EBITDA fell to 3.55 from 3.96.
- Growth came from the recurring, higher-margin consumables business; customers stayed cautious on bioprocess equipment and lab instruments, which stabilized over the year. Recurring single-use products are just above three-quarters of Bioprocess Solutions sales.
- Regions: EMEA €1,466.6 million (around 42%), Americas €1,251.4 million (35%), Asia | Pacific €820.1 million (around 23%); almost half of sales come from the 50 largest customers, none above 5%.
- Capex was €441.9 million (12.5% of sales); the largest project is a new consumables plant in Songdo, South Korea, alongside Freiburg (cell and gene therapy components) and Göttingen (membranes and filters); Aubagne (France) was expanded.
- Michael Grosse became CEO on July 1, 2025, succeeding Joachim Kreuzburg, and launched a strategy project; MATTEK (3D cell models) was acquired on July 1, 2025.
- 2026 guidance: sales growth of around 5 to 9% in constant currencies, underlying EBITDA margin slightly above 30%, capex ratio around 12.5%, leverage slightly above 3; Bioprocess Solutions +6 to 10%, Lab Products & Services +2 to 6%.
- Competitors named: Danaher, Merck KGaA and Thermo Fisher in both divisions; Mettler-Toledo (balances), Eppendorf (pipettes), Agilent, Becton Dickinson and Revvity (cell analytics). Key risks: customer capex restraint, US tariffs, gene-therapy acquisitions developing below expectations, FX.

### [First-Half Financial Report January to June 2026](https://www.sartorius.com/download/1845862/h1-2026-download-half-year-report-sag-en-data.pdf)

Interim report · 2026-07-23

- H1 2026 sales revenue €1,810.9 million: +7.7% operational growth in constant currencies (excluding intended customer compensation for refunded US tariffs), +6.2% in constant currencies including it, +2.5% reported.
- Consumables and services remained the main growth driver; equipment and instruments stabilized and returned to modest growth. MATTEK added 0.5 percentage points.
- Underlying EBITDA rose 3.9% to €547.8 million, margin 30.3% (29.8%); net profit after minorities €122.2 million (€81.0 million); free cash flow €207.7 million (+70.4%).
- Bioprocess Solutions: €1,475.5 million, +8.3% operational / +6.7% cc, margin 32.3%; Lab Products & Services: €335.4 million, +5.3% operational / +4.3% cc (MATTEK 2.8 points), margin 21.2%.
- Regions (cc): EMEA +7.2% to €784.2 million; Americas +1.2% (+5.6% excluding the tariff compensation) to €608.0 million; Asia | Pacific +12.1% to €418.7 million on a recovery in China.
- After the US Supreme Court ruled IEEPA tariffs unlawful in February 2026, Sartorius received refunds and booked around €26 million of customer compensation, reducing sales; compensation could cut revenue by up to €40 million versus initial assumptions.
- 2026 guidance confirmed: group +5 to 9% cc (lower half including tariff compensation, midpoint operationally), margin slightly above 30%, leverage slightly above 3; leverage 3.51 at June 30.
- Mid-term targets set at the March 2026 Capital Markets Day: organic growth of 8 to 11% a year from 2027 (Bioprocess 9 to 12%, Lab 5 to 7%) and +50 to 75 bp margin a year; addressable markets seen growing about 7 to 9%.
- A €500 million 3.75% bond was issued in May 2026 to refinance the 2026 maturity; the remaining 24% of Sartorius CellGenix (about €71.8 million) and 37.5% of Sartorius Automated Lab Solutions (€14.0 million, July 2026) were bought out.

### [Preliminary Results 2025 conference call (Q4 FY2025 earnings call transcript)](https://www.roic.ai/quote/SOAGY/transcripts/2025-year/4-quarter)

Executive talk · Michael Grosse, CEO · 2026-02-03

- On the preliminary FY2025 call (February 3, 2026), CEO Michael Grosse described 2025 as a return to normal consumables demand with continued cautious customer investment, and results slightly ahead of upgraded guidance (sales +7.6% cc, margin 29.7%).
- CFO Florian Funck: recurring business grew mid-teens; tariff surcharges added about 1 point of growth; the weaker US dollar cost almost 300 bp of reported growth; order intake grew faster than sales and Q4 was the year's strongest order quarter.
- Free cash flow was €390 million; leverage fell to 3.55x from 3.96x; the company stays committed to its investment-grade rating.
- 2026 guidance: group +5 to 9% cc, margin slightly above 30% after about 50 bp tariff dilution; Grosse said "we will not celebrate if we achieve only a 6% growth".
- US reshoring is not in 2026 guidance; Grosse expects any relevant revenue in 2027 and beyond, given equipment lead times of 6 to 12 months.
- René Fáber: around 80% of bioprocess consumables revenue is tied to late-stage clinical and commercial manufacturing; Sartorius kept roughly 1/3 of its pandemic share gains.
- China: Grosse sees the "rebaselining" ending but expects a flattish, modest market in 2026, especially in equipment.
- Capex ratio to come down from 2027; 2026 is the last elevated year, driven by Korea. Funck called Lab Products & Services "a 20% plus margin business".

### [H1 2026 results conference call (Q2 FY2026 earnings call transcript)](https://www.roic.ai/quote/SOAGY/transcripts/2026-year/2-quarter)

Executive talk · Michael Grosse, CEO · 2026-07-23

- On the H1 2026 call (July 23, 2026), CEO Michael Grosse said customer demand for high-performance single-use products, reagents and productivity technology "is bigger than ever before" and that using AI for speed in drug discovery and bioprocessing "is becoming a must".
- Operational group growth was 7.7%: recurring business slightly more than 9%, equipment around 2%; Grosse said the equipment return to growth "reinforces our view that the bottom is behind us".
- Tariff refunds: €26 million of customer compensation booked in H1 (about €40 million applied for in total); Grosse said "we were caught by surprise" and that compensating customers is "a momentum of trust and partnership".
- Recurring growth was diluted by delayed late-stage orders from 2 advanced-therapy customers, mostly in the Americas; orders are expected at year-end, with revenue mostly in 2027.
- CFO Florian Funck: consumables volume in H1 2026 exceeds the pandemic peak; free cash flow +70%; leverage 3.5x; the May bond was significantly oversubscribed.
- Launches: Pionic Quad & Cross modules (fully integrated continuous downstream), a new Ambr 250 vessel, Cubis III balances; Incucyte won 3 new top-10 pharma customers this year.
- Reshoring now turning into brownfield projects; most related orders are expected in H2 2027, with sales in 2028 and beyond.
- 2026 guidance confirmed: group +5 to 9% cc, margin slightly above 30%; operationally around the midpoint. Grosse declined to discuss 2027.

## Questions about Sartorius

### What does Sartorius do?

Sartorius supplies the biopharmaceutical industry and life science research with bioprocess equipment, single-use consumables, filtration, cell culture products, lab instruments and bioanalytics.

### What is Sartorius' revenue?

2025 sales revenue was €3,538.1 million, up 7.6% in constant currencies, with underlying EBITDA of €1,051.6 million; H1 2026 sales were €1,810.9 million.

### How many employees does Sartorius have?

14,042 at the end of 2025 and 14,279 at June 30, 2026.

### Who leads Sartorius?

Dr. Michael Grosse has been CEO since July 1, 2025, succeeding Dr. Joachim Kreuzburg; Dr. Florian Funck is CFO.

### What is Sartorius' strategy?

Above-market profitable growth through portfolio development, regional growth in North America and Asia and process optimization, targeting 8 to 11% organic growth a year from 2027.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
